COST-UTILITY ANALYSIS OF EXERCISE FOR THE PREVENTION OF CANCER

Author(s)

O'Day K1, Campbell DJ2
1Xcenda, LLC, Palm Harbor, FL, USA, 2Xcenda, Palm Harbor, FL, USA

OBJECTIVES:  The benefits of exercise for cardiovascular health are widely known. A recent meta-analysis reported an association between exercise and a reduction in the risk of cancer. This study aims to assess the cost-utility of exercise for the prevention of cancer from a US health-system perspective. METHODS:  A cohort life-table analysis was developed to model life years (LYs) and quality-adjusted life years (QALYs) of low versus high physical activity over a lifetime horizon in US adults. Hazard ratios for various cancers (bladder, breast, colorectal, endometrial, esophageal, gastric, head/neck, kidney, liver, lung, leukemia and myeloma) were obtained from a meta-analysis. Age- and sex-specific incidence and mortality rates were obtained from SEER. Utility weights, baseline healthcare costs, and attributable cancer costs were obtained from the literature. Three exercise programs of varying costs were considered including exercising at home, gym membership, and gym with personal trainer. Incremental analyses, stratified by sex, and probabilistic sensitivity analyses (PSAs) were conducted. RESULTS:  High activity levels, compared to low, increased undiscounted LYs by 0.37 and 0.34 years and discounted QALYs by 0.07 and 0.06 years for males and females, respectively. High activity reduced lifetime cancer costs by $1,873 and $1,593 and lifetime healthcare costs by $779 and $462, respectively, for males and females. The incremental cost per QALY inclusive of low, moderate and high exercise costs were $88,780, $279,980, and $825,071 for males and $99,063, $300,893 and $876,288 for females, respectively. In the PSA low cost exercise had a 15.6% and 11.9% probability of being cost-effective for males and females, respectively, at a $50,000/QALY threshold. CONCLUSIONS:  Despite many associated health benefits, exercise may not be a cost-effective means for cancer prevention – this may have implications for potential pharmacologic interventions to prevent cancer. Given the limitations of observational study data, further research is warranted to confirm these findings.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN178

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×